Glenview Trust co Has $266,000 Stock Position in GSK plc (NYSE:GSK)

Glenview Trust co reduced its stake in shares of GSK plc (NYSE:GSK) by 12.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 7,869 shares of the pharmaceutical company’s stock after selling 1,068 shares during the quarter. Glenview Trust co’s holdings in GSK were worth $266,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of GSK. FMR LLC boosted its stake in GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after buying an additional 2,224,345 shares in the last quarter. Fisher Asset Management LLC boosted its stake in GSK by 4.9% in the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after buying an additional 870,449 shares in the last quarter. Clifford Capital Partners LLC boosted its stake in GSK by 14.3% in the third quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company’s stock valued at $16,747,000 after buying an additional 51,378 shares in the last quarter. Cerity Partners LLC boosted its stake in GSK by 61.8% in the third quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company’s stock valued at $17,728,000 after buying an additional 165,556 shares in the last quarter. Finally, Natixis Advisors LLC boosted its stake in GSK by 20.0% in the third quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company’s stock valued at $20,460,000 after buying an additional 83,433 shares in the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Price Performance

GSK stock opened at $40.30 on Tuesday. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. The company has a market capitalization of $83.53 billion, a PE ratio of 25.35, a P/E/G ratio of 1.12 and a beta of 0.58. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.93. The stock has a 50-day moving average price of $36.18 and a two-hundred day moving average price of $36.99.

GSK (NYSE:GSK) last posted its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Analysts expect that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be given a dividend of $0.3932 per share. This represents a $1.57 dividend on an annualized basis and a dividend yield of 3.90%. This is an increase from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. GSK’s dividend payout ratio (DPR) is 98.74%.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Morgan Stanley assumed coverage on GSK in a research note on Wednesday, February 12th. They issued an “equal weight” rating on the stock. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Seven analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. According to MarketBeat.com, GSK currently has a consensus rating of “Moderate Buy” and an average price target of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.